Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AVIL is a bona fide oncogene in rhabdomyosarcoma

ABSTRACT: 1. AVIL forms a protein-coding fusion with MARS in rhabdomyosarcoma. 2. AVIL is amplified in some RMSs, and overexpressed in most of the RMSs we tested. 3. Tumor cells are addicted to the MARS-AVIL fusion or overexpression of AVIL. 4. Higher AVIL expression correlates with poor prognosis in sarcoma patients

ORGANISM(S): Homo sapiens

PROVIDER: GSE173247 | GEO | 2026/05/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Rhabdomyosarcomas are oncogene addicted to the activation of AVIL

Project description:Rhabdomyosarcoma (RMS) is one of the most common pediatric soft-tissue cancer. Previously, we discovered a gene fusion, MARS-AVIL formed by chromosomal inversion in RMS. Suspecting that forming a fusion with a housekeeping gene may be one of the mechanisms to dysregulate an oncogene, we investigated AVIL expression and its role in RMS. We first showed that MARS-AVIL translates into an in-frame fusion protein, which is critical for the RMS cell tumorigenesis. Besides forming a gene fusion with the housekeeping gene, MARS, the AVIL locus is often amplified, and its RNA and protein expression is overexpressed in the majority of RMSs. Tumors with AVIL dysregulation exhibit evidence of oncogene addiction: silencing MARS-AVIL in cells harboring the fusion, or silencing AVIL in cells with AVIL overexpression, nearly eradicated the cells in culture, as well as inhibited in vivo xenograft growth in mice. Conversely, gain-of-function manipulations of AVIL led to increased cell growth and migration, enhanced foci formation in mouse fibroblasts, and most importantly transformed mesenchymal stem cells in vitro and in vivo. Mechanistically, AVIL seems to serve as a converging node functioning upstream of two oncogenic pathways, PAX3-FOXO1 and RAS, thus connecting two types of RMS associated with these pathways. Interestingly, AVIL is overexpressed in other sarcoma cells as well, and its expression correlates with clinical outcomes, with higher levels of AVIL expression being associated with worse prognosis. AVIL is a bona fide oncogene in RMS, and RMS cells are addicted to its activity.

2022-06-07 | GSE180837 | GEO

Rhabdomyosarcomas are oncogene addicted to the activation of AVIL

Project description:Rhabdomyosarcomas are oncogene addicted to the activation of AVIL

| PRJNA749758 | ENA

Gastric Cancer AVIL overexpression and pharmacologic inhibition in GES1 and AGS cell lines.

Project description:AVIL is an oncogenic driver of gastric cancer. To test the oncogenic ability of AVIL, we established stable AVIL overexpression in normal human gastric epithelial cell line GES1 and performed RNA-sequence. We also use AVIL inhibitor compound A to treat gastric cancer cell line AGS and do transcriptome analysis.

2026-01-01 | GSE287892 | GEO

Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members

Project description:Rhabdomyosarcoma (RMS) is a highly malignant tumour accounting for nearly half of soft tissue sarcomas in children. Altered miRNA levels have been reported in human cancers, including RMS. Using deep sequencing technology, a total of 685 miRNAs were investigated in a group of alveolar RMSs (ARMSs), embryonal RMSs (ERMSs) as well as in normal skeletal muscle (NSM). Bioinformatics pipelines were used for miRNA target prediction and clustering analysis. Ninety-seven miRNAs were significantly deregulated in ARMS and ERMS when compared to NSM. MiR-378 family members were dramatically decreased in RMS tumour tissue and cell lines. Interestingly, members of the miR-378 family presented as a possible target the insulin-like growth factor receptor 1 (IGF1R), a key signalling molecule in RMS.

2015-01-28 | E-MTAB-3246 | biostudies-arrayexpress

Expression Profiling of human Fusion-Positive and Fusion-Negative Rhabdomyosarcoma

Project description:Genome-wide gene expression in 33 fusion-positive and 25 fusion-negative rhabdomyosarcoma cases was studied using GeneChip Human Genome U133 Plus2 (Affymetrix) Fusion-positive versus fusion-negative rhabdomyosarcoma tumors

2016-06-01 | E-GEOD-66533 | biostudies-arrayexpress

A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma

Project description:Total RNA extracted from knockdown or overexpress AVIL in GBM U87 cells. and RNA-seq after sample quality control.

2020-06-08 | GSE95164 | GEO

Fusion Negative Rhabdomyosarcoma Cell Lines

Project description:Fusion Negative Rhabdomyosarcoma Cell Lines

| PRJNA330685 | ENA

Effect of PAX3-WWTR1 knockdown in rhabdomyosarcoma derived tumoroids

Project description:In this study, we sought to understand the effects of a rare PAX3-WWTR1 fusion in a tumoroid line derived from an embryonal rhabdomyosarcoma sample through fusion knockdown.

2025-02-28 | E-MTAB-13715 | biostudies-arrayexpress

CD74-NRG1 fusion as an bona fide oncogene

Project description:CD74-NRG1 fusion as an bona fide oncogene

| PRJNA762691 | ENA

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma

Project description:To date, there are no known prognostic markers identified in patients with fusion gene-negative rhabdomyosarcoma. This study validates the 5-gene (MG5) signature as a prognostic marker in patients with fusion negative intermediate-risk rhabdomyosarcoma clearly stratifying this otherwise clinically homogenous population of patients into two risk groups based on outcome. In addition, this analysis was performed using nCounter assay on paraffin embedded tissues and the results were concordant to previously published results using frozen tissues in a different patient cohort. Therefore, this work holds tremendous translational relevance as the MG5 signature can be reliably assessed in readily available paraffin embedded tissues of fusion gene-negative rhabdomyosarcoma patients in prospective clinical trials to stratify them into prognostic risk groups as well as to potentially tailor future therapy based on these risk groups.

2015-07-31 | E-MTAB-3580 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data